Self-inhibited State of Venezuelan Equine Encephalitis Virus (VEEV) nsP2 Cysteine Protease: A Crystallographic and Molecular Dynamics Analysis.


Journal

Journal of molecular biology
ISSN: 1089-8638
Titre abrégé: J Mol Biol
Pays: Netherlands
ID NLM: 2985088R

Informations de publication

Date de publication:
15 03 2023
Historique:
received: 03 11 2022
revised: 06 02 2023
accepted: 07 02 2023
pubmed: 16 2 2023
medline: 7 3 2023
entrez: 15 2 2023
Statut: ppublish

Résumé

The Venezuelan equine encephalitis virus (VEEV) belongs to the Togaviridae family and is pathogenic to both humans and equines. The VEEV non-structural protein 2 (nsP2) is a cysteine protease (nsP2pro) that processes the polyprotein and thus it is a drug target for inhibitor discovery. The atomic structure of the VEEV nsP2 catalytic domain was previously characterized by both X-ray crystallography and computational studies. A modified nsP2pro harboring a N475A mutation in the N terminus was observed to exhibit an unexpected conformation: the N-terminal residues bind to the active site, mimicking binding of a substrate. The large conformational change of the N terminus was assumed to be induced by the N475A mutation, as N475 has an important role in stabilization of the N terminus and the active site. This conformation was first observed in the N475A mutant, but we also found it while determining a crystal structure of the catalytically active nsP2pro containing the wild-type N475 active site residue and K741A/K767A surface entropy reduction mutations. This suggests that the N475A mutation is not a prerequisite for self-inhibition. Here, we describe a high resolution (1.46 Å) crystal structure of a truncated nsP2pro (residues 463-785, K741A/K767A) and analyze the structure further by molecular dynamics to study the active and self-inhibited conformations of nsP2pro and its N475A mutant. A comparison of the different conformations of the N-terminal residues sheds a light on the interactions that play an important role in the stabilization of the enzyme.

Identifiants

pubmed: 36792007
pii: S0022-2836(23)00068-2
doi: 10.1016/j.jmb.2023.168012
pii:
doi:

Substances chimiques

Cysteine Proteases EC 3.4.-
nsP2 proteinase EC 3.4.22.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

168012

Subventions

Organisme : NCI NIH HHS
ID : 75N91019D00024
Pays : United States
Organisme : NCRR NIH HHS
ID : S10 RR025528
Pays : United States
Organisme : NCRR NIH HHS
ID : S10 RR028976
Pays : United States
Organisme : NIH HHS
ID : S10 OD027000
Pays : United States

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Gyula Hoffka (G)

Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Hungary; Doctoral School of Molecular Cell and Immune Biology, University of Debrecen, Debrecen, Hungary.

George T Lountos (GT)

Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.

Danielle Needle (D)

Center for Structural Biology, National Cancer Institute, Frederick, MD 21702, USA.

Alexander Wlodawer (A)

Center for Structural Biology, National Cancer Institute, Frederick, MD 21702, USA.

David S Waugh (DS)

Center for Structural Biology, National Cancer Institute, Frederick, MD 21702, USA.

József Tőzsér (J)

Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Hungary.

János András Mótyán (JA)

Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Hungary. Electronic address: motyan.janos@med.unideb.hu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH